References
- Hughes TP, Kaeda J, Branford S, et al. International Randomised Study of Interferon versus STI571 (IRIS) Study Group. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003;349:1423–1432.
- Jabbour EJ, Cortes JE, Kantarjian HM. Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options. Clin Lymphoma Myeloma Leuk 2013;13:515–529.
- Crews LA, Jamieson CH. Chronic myeloid leukemic stem cell biology. Curr Haematol Malign Rep 2012;7:125–132.
- Esposito N, Colavita I, Quintarelli C, et al. SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia. Blood 2011;118:3634–3644.
- Neviani P, Santhanam R, Trotta R, et al. The tumour suppressor PP2A is functionally inactivated in blast crisis CML through the inhibitory activity of the BCR/ABL regulated SET protein. Cancer Cell 2005;8:355–368.
- Kaeda J, O’Shea D, Szydlo RM, et al. Serial measurement of BCR-ABL transcripts in the peripheral blood after allogeneic stem cell transplant for chronic myeloid leukemia. An attempt to define patients who may not require further therapy. Blood 2006;107:4171–4176.
- Bruecher-Encke B, Griffin JD, Neel BG, et al. Role of the tyrosine phosphatase SHP-1 in K562 cell differentiation. Leukemia 2001;15: 1424–1432.
- Amin HM, Hoshino K, Yang H, et al. Decreased expression level of SH2 domain-containing protein tyrosine phosphatase-1 (Shp1) is associated with progression of chronic myeloid leukemia. J Pathol 2007;212:402–410.
- Neviani P, Harb JG, Oaks JJ, et al. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells. J Clin Invest 2013;123:4144–4157.